-
Part i of CPhI Annual Report highlights unpredictability in CDMO growth over next five years
pharmaasia
October 23, 2017
CPhI report shows growth in flow chemistry, overseas funds repatriation, API/product integration etc., but the rate of change remains unclear.
-
CPhI Worldwide 2017：Anticipated CDMO Market Trends in CPhI Report
contractpharma
October 18, 2017
Niche services and technologies to dominate future acquisitions, increase in flow chemistry, fermentation anticipated
-
Amatsigroup Manufactures Injectable Clinical Batch Under Single-Use Isolator
contractpharma
September 06, 2017
French CDMO develops innovative single-use technology solutions for aseptic formulation & manufacturing
-
QS Pharma receives approval from European Medicines Agency
pharmaasia
August 04, 2017
QS Pharma, a Quotient Clinical business, is now approved to manufacture medicinal products for the US, Europe and Japan.
-
Outsourcing: Current trends in the CDMO sector
europeanpharmaceuticalreview
July 04, 2017
Patheon’s Joe Principe examines current trends in outsourcing, highlighting the importance of investment in CDMO partnerships…
-
Fujifilm Diosynth Biotechnologies announce successful completion of its 100th paveway
europeanpharmaceuticalreview
July 03, 2017
Fujifilm Diosynth Biotechnologies has announced the successful completion of its 100th program using its pAVEway? Advanced Protein Expression system…
-
Juniper Pharma Services brings PSD-1 spray dryer online
cphi-online
June 27, 2017
The addition enables the CDMO to scale-up early-phase bench top processes to support later stage clinical development and niche, low volume manufacturing requirements.
-
CoreRx, Aimmune Unveil Joint Expansion
contractpharma
June 14, 2017
Together will advance treatment of peanut and other food allergies
-
Rentschler Biotechnologie and Rentschler Fill Solutions Announce Strategic Partnership for One-Stop
b3cnewswire
June 13, 2017
Rentschler Biotechnologie GmbH today announced a strategic partnership to provide new state-of-the-art fill and finish facilities and one-stop solutions for biopharmaceutical products to meet the needs of Rentschler Biotechnologie’s clients.
-
CE Mark for Implandata's EYEMATE? System for Improved Monitoring and Management of Glaucoma Patients
b3cnewswire
June 01, 2017
apceth Biopharma GmbH, a cell therapy company with a proprietary portfolio of genetically modified mesenchymal stem cell therapeutics for the treatment of inflammatory diseases and cancer.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
